Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumorsSerena Di Cosimo, Francesco Cognetti, G. Ferretti et al.|Drugs of today|2003Cited by 168
Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer PatientsG. Ferretti, F. Cognetti, Alessandra Fabi et al.|Oncology|2005Cited by 133
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and CyclophosphamidePaola Papaldo, F. Calabresi, Massimo Lopez et al.|Journal of Clinical Oncology|2005Cited by 96
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Antonio Ardizzoia et al.|The Lancet Oncology|2018Cited by 88
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive diseasePaola Papaldo, F. Cognetti, Alessandra Fabi et al.|Annals of Oncology|2006Cited by 82